Levels of CCL18 in the serum from peripheral blood of SCCHN patients were significantly higher than the precancerous lesions of SCCHN patients and healthy controls, which suggested that serum CCL18 levels can serve as a potentially useful biomarker for the diagnosis and prognosis of SCCHN. The gene discussed is CCL18; the disease is head and neck squamous cell carcinoma.